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Deoxycoformycin (DCF) has recently emerged as a useful
therapeutic agent in the treatment of mature B-cell malignan-
cies. This drug is a potent inhibitor of adenosine deaminase
(ADA), a key enzyme in the purine salvage pathway, respon-
sible for the irreversible degradation of adenosine to deoxy-
adenosine. The exact mechanism of cytotoxicity of DCF
remains unknown. Congenital ADA deficiency is responsible
for severe combined immunodeficiency characterised by selec-
tive impairment of lymphoid development (Dissing &
Knudsen, 1972), so clearly this enzyme plays a vital role in
normal lymphocyte differentiation and function. Indeed,
although the enzyme is widely distributed, the greatest
activity is found in cells of the lymphoid system. The activity
is higher in T cells than in B cells and this relationship is
maintained in their neoplastic counterparts (Hoffbrand et al.,
1982). This higher level of activity in T cells provided a
rationale for therapeutic trials in the late 1970s and early
1980s in T-cell ALL (Prentice et al., 1980). However, the high
doses of DCF used in these studies resulted in severe and
unpredictable toxicity which limited its clinical usefulness.
Since total inhibition of tumour cell ADA activity appears to
be required to achieve a therapeutic effect (Grever et al.,
1981), it might be predicted that malignant cells expressing
lower levels of ADA activity would in fact require lower
doses of DCF. This presupposition has been confirmed by
clinical trials demonstrating an encouraging response to DCF
treatment in the mature B and T cell malignancies in which
ADA levels are low by comparison with lymphoblastic
leukaemia (Ho et al., 1988). Careful pharmacological studies
have enabled a safe and effective treatment schedule to be
defined which is able to produce prolonged ADA inhibition
in neoplastic cells. The most sensitive malignancy so far
identified is hairy cell leukaemia (HCL) and over the past few
years a number of phase II trials have aimed to define more
precisely the role of DCF in the treatment of HCL and other
mature B cell malignancies such as chronic lymphocytic
leukaemia (CLL). We have treated a range of mature B cell
malignancies with a low dose, 4 mg m2, every 1-2 weeks.
At this dose the drug is generally well tolerated by patients
with no serious toxicity.
Hairy cell leukaemia
Fifty-eight patients with HCL have been entered into our
study (Dearden & Catovsky, 1990), of whom 44 are currently
evaluable for response. The overall response rate in this
group is 98% (Table I), the majority being complete remis-
sions (CR) and these results have been achieved after a
relatively short period of treatment (3-6 months). Five out
of six patients in our series who previously had a poor
response to interferon-alpha responded to DCF with com-
plete or partial remissions (PR). Unmaintained remissions
have lasted for a median of 13 months with a range up to 45
months. Only one of the complete remitters has relapsed
after 18 months off therapy and is currently responding again
to DCF treatment.
Table I Treatment of mature B-cell malignancies with
deoxycoformycin (the Royal Marsden Hospital series)
Patients Overall Duration of
evaluable response rate response (months)
Diagnosis for response CR PR (CR +PR) median (range)
HCL 44 34 9a 98% 13 (3-45)
B-CLL 17 0 6 35% 6 (3-18)
B-PLL 4 2 50% (4-22)
B-NHL 3 0 2 67% 15 (12-19)
Total 67 34 19 79%
HCL, hairy cell leukaemia; CLL, chronic lymphocytic leukaemia;
PLL, prolymphocytic leukaemia of B-cell type; NHL, non-Hodgkin's
lymphoma of B-cell type. a4 still on therapy and may yet reach CR.
Other groups undertaking clinical trials of DCF in the
treatment of HCL have reported similar results, with overall
response rates in excess of 80% in all series. Complete remis-
sions are seen in 56% (Grem et al., 1989) to 89% (Johnston
et al., 1986) of patients. Interestingly, equally good results
have been observed by those groups using a lower dose of
DCF (4 mg m-2) every 2 weeks (Kraut et al., 1986) as those
using higher doses (5 mg m-2) for 2 days every 2 weeks
(Spiers et al., 1987) and with considerably less toxicity.
Indeed, only 1% of HCL patients treated in clinical trials
using DCF at 4 mg m-2 every other week have died during
therapy. These results are an improvement on those achieved
with interferon-alpha where, although the overall response
rates are similar at 80%, the proportion of patients achieving
CR is variable and generally not high (<50%). In our
experience of 31 HCL patients treated with interferon-alpha
for a median of 16 months (6-68 +) the CR rate was 39%.
Furthermore, relapse after treatment has stopped is the rule
and this commonly occurs within the first 12-18 months off
therapy.
The treatment of HCL with DCF, although highly
effective, is not entirely free ofcomplications. This drug has a
profound effect on immune function, decreasing all lympho-
cyte subpopulations for prolonged periods (Urba et al.,
1989). This, added to the existing problems of neutropenia
and monocytopenia in HCL patients, puts them at con-
siderable risk of severe infections during treatment. Careful
management with the use of antibiotic, antifungal and
antiviral prophylaxis seems to help in reducing this risk but is
not effective in all cases. Our studies suggest there may still
be a role for interferon-alpha in the initial therapy of HCL to
reduce infections associated with DCF treatment. Twelve
patients were treated with interferon-alpha for 2-6 months
immediately before commencing DCF. This group had fewer
infectious complications than a group ofpatients treated only
with DCF. This suggests that an area of future study might
be to compare, in a randomised controlled trial, the initial
treatment with interferon-alpha for 6 months followed by
DCF until remission, with the use of DCF alone.
Chronic lymphocytic leukaemia
CLL is a lymphoproliferative disorder commonly affecting
people over the age of 50. The prognosis varies widely and
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although this relates to the clinical and haematological stag-
ing it also appears that patients who respond to treatment
survive significantly longer than those who do not (Catovsky
et al., 1988). Current standard therapy for CLL, with
alkylating agents, is effective in producing an objective re-
sponse in about 50-70% of patients. Patients who fail to
respond or become resistant to conventional agents present a
management problem and require innovative therapy.
Deoxycoformycin is one of three new agents recently pro-
duced which appear to be active in this disease and may
improve survival of patients with advanced CLL. The two
other agents, fludarabine and 2-chlorodeoxyadenosine, are
structurally related to DCF and share the same range of
disease activity. Of these, fludarabine has been shown to be
effective in CLL in comparative trials in the USA and
Europe (Keating et al., 1988). A smaller study by Piro et al.
(1988) indicates that 2-chlorodeoxyadenosine may also have
therapeutic potential in this disease.
Our experience in the treatment of B-CLL with DCF has
been confined to advanced patients (stage C) who had
previously received one or more treatments and were no
longer responsive to them. In this resistant group a response
rate of 35% was achieved (Table I). One of these patients has
been treated for more than 3 years and is currently on a third
course of DCF to which he is again responding. Other phase
II trials have reported a response rate of 18-26% in heavily
pre-treated patients with CLL (Table II), with a further
20-30% experiencing clinical improvement. Dillman et al.
(1989) pointed out that less toxicity and better responses are
seen in patients with stage B disease who had not been
heavily pre-treated.
Combinations of DCF with both conventional therapies
and other investigational agents such as fludarabine are also
currently being evaluated (Cheson, 1989). Preliminary results
suggest that the major drawback of such regimes, particularly
in patients with advanced disease, is the high risk of infec-
tions.
Table II Studies with deoxycoformycin in the treatment of CLL
Author Disease No. of Response
(year) stage patients CR PR Overall
Grever (1985) C 28 1 4 18%
O'Dwyer (1988) C 29 1 6 24%
Dillman (1989) B & C 39 1 9 26%
This study C 17 0 6 35%
Total B & C 113 3 25 25%
Other B-cell disorders
We have also treated with DCF some patients with B-
prolymphocytic leukaemia and refractory non-Hodgkin's
lymphoma (Table I). Although the numbers are small, it is
worth recording that there were two partial responses in each
group and one patient with B-prolymphocytic leukaemia was
in stable PR for 22 months. These results are encouraging in
cases where the prognosis is otherwise very poor. However,
further evaluation is needed in order to confirm this early
optimism.
In conclusion, DCF has proved to be a valuable addition
to the current range of chemotherapeutic agents for the
treatment of B-cell malignancies. In particular, it is clear that
it is currently the most effective therapy for HCL and the
major task now is to tackle the problem of infectious compli-
cations and to evaluate the role of interferon-alpha in pro-
tecting against them by improving the haematological status
of the patient before the use of DCF. Its true efficacy in
other B cell disorders, such as B-CLL and PLL, has yet to be
fully evaluated, especially in the treatment of early cases, but
the existing data are encouraging.
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